Review article: Vitamin D and inflammatory bowel disease - Established concepts and future directions

Alimentary Pharmacology and Therapeutics

Volumn 36, Issue 4, 2012, Pages 324-344

  Garg, M ^a,b,c   Lubel, J S ^a   Sparrow, M P ^d   Holt, S G ^a,b   Gibson, P R ^a,d  

^a Eastern Health ^*  (Australia)

^b MONASH UNIVERSITY   (Australia)

^c AUSTIN HOSPITAL   (Australia)

^d ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

22 OXACALCITRIOL; ALFACALCIDOL; CALCIPOTRIOL; CALCITRIOL; CALCIUM CARBONATE; COLECALCIFEROL; DOXERCALCIFEROL; ERGOCALCIFEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; PARICALCITOL; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D; VITAMIN D BINDING PROTEIN; VITAMIN D RECEPTOR;

ADAPTIVE IMMUNITY; BINDING AFFINITY; BONE DENSITY; CALCIUM ABSORPTION; CALCIUM HOMEOSTASIS; CANCER PREVENTION; CELL DIFFERENTIATION; CHROMATIN IMMUNOPRECIPITATION; CHRONIC KIDNEY DISEASE; CROHN DISEASE; ENTERITIS; FRACTURE; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GLYCOSYLATION; HUMAN; HYDROXYLATION; HYPERCALCEMIA; HYPERCALCIURIA; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; INCIDENCE; INNATE IMMUNITY; KIDNEY PROXIMAL TUBULE; MAPK SIGNALING PATHWAY; MENOPAUSAL SYNDROME; MUSCULOSKELETAL DISEASE; NONHUMAN; OSTEOBLAST; OSTEOLYSIS; OSTEOPOROSIS; PARATHYROID GLAND; PHOSPHATE METABOLISM; POSTMENOPAUSE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN BINDING; REVIEW; SEX DIFFERENCE; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; T LYMPHOCYTE; ULTRAVIOLET B RADIATION; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN D INTOXICATION; VITAMIN METABOLISM;

BONE DENSITY; HUMANS; INFLAMMATORY BOWEL DISEASES; VITAMIN D; VITAMIN D-BINDING PROTEIN;

EID: 84863988583     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.05181.x     Document Type: Review

References (221)

1. Wilson J, Hair C, Knight R, et al,. High incidence of inflammatory bowel disease in Australia: a prospective population-based Australian incidence study. Inflamm Bowel Dis 2010; 16: 1550-6.
2. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A,. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011; 140: 1785-94.
3. Loftus EV Jr,. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004; 126: 1504-17.
4. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al,. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 1911-30.
5. Thacher TD, Clarke BL,. Vitamin D insufficiency. Mayo Clin Proc 2011; 86: 50-60.
6. Jones G,. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr 2008; 88: 582S-6S.
7. Holick MF,. Vitamin D deficiency. N Engl J Med 2007; 357: 266-81.
8. Omdahl JL, Morris HA, May BK,. Hydroxylase enzymes of the vitamin D pathway: expression, function, and regulation. Annu Rev Nutr 2002; 22: 139-66.
9. Mawer EB, Backhouse J, Holman CA, Lumb GA, Stanbury SW,. The distribution and storage of vitamin D and its metabolites in human tissues. Clin Sci 1972; 43: 413-31.
10. Vicchio D, Yergey A, O'Brien K, Allen L, Ray R, Holick M,. Quantification and kinetics of 25-hydroxyvitamin D3 by isotope dilution liquid chromatography/thermospray mass spectrometry. Biol Mass Spectrom 1993; 22: 53-8.
11. Vieth R, ed. The Pharmacology of Vitamin D, Including Fortification Strategies. 2nd edn. London: Elsevier, 2005.
12. Powe CE, Ricciardi C, Berg AH, et al,. Vitamin D-binding protein modifies the vitamin D-bone mineral density relationship. J Bone Miner Res 2011; 26: 1609-16.
13. Otterbein LR, Cosio C, Graceffa P, Dominguez R,. Crystal structures of the vitamin D-binding protein and its complex with actin: structural basis of the actin-scavenger system. Proc Natl Acad Sci USA 2002; 99: 8003-8.
14. Kawakami M, Imawari M, Goodman DS,. Quantitative studies of the interaction of cholecalciferol (vitamin D3) and its metabolites with different genetic variants of the serum binding protein for these sterols. Biochem J 1979; 179: 413-23.
15. Haddad JG Jr., Walgate J,. 25-Hydroxyvitamin D transport in human plasma. Isolation and partial characterization of calcifidiol-binding protein. J Biol Chem 1976; 251: 4803-9.
16. Plum LA, DeLuca HF,. Vitamin D, disease and therapeutic opportunities. Nat Rev Drug Discov 2010; 9: 941-55.
17. Zimmerman DR, Reinhardt TA, Kremer R, Beitz DC, Reddy GS, Horst RL,. Calcitroic acid is a major catabolic metabolite in the metabolism of 1 alpha-dihydroxyvitamin D(2). Arch Biochem Biophys 2001; 392: 14-22.
18. Chishimba L, Thickett DR, Stockley RA, Wood AM,. The vitamin D axis in the lung: a key role for vitamin D-binding protein. Thorax 2010; 65: 456-62.
19. Nykjaer A, Dragun D, Walther D, et al,. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 1999; 96: 507-15.
20. Rowling MJ, Kemmis CM, Taffany DA, Welsh J,. Megalin-mediated endocytosis of vitamin D binding protein correlates with 25-hydroxycholecalciferol actions in human mammary cells. J Nutr 2006; 136: 2754-9.
21. Atkins GJ, Anderson PH, Findlay DM, et al,. Metabolism of vitamin D3 in human osteoblasts: evidence for autocrine and paracrine activities of 1 alpha,25-dihydroxyvitamin D3. Bone 2007; 40: 1517-28.
22. van Driel M, Koedam M, Buurman CJ, et al,. Evidence for auto/paracrine actions of vitamin D in bone: 1alpha-hydroxylase expression and activity in human bone cells. FASEB J 2006; 20: 2417-9.
23. Chun RF, Lauridsen AL, Suon L, et al., Vitamin D-binding protein directs monocyte responses to 25-hydroxy- and 1,25-dihydroxyvitamin D. J Clin Endocrinol Metab 2010; 95: 3368-76.
24. Thrailkill KM, Jo CH, Cockrell GE, Moreau CS, Fowlkes JL,. Enhanced excretion of vitamin D binding protein in type 1 diabetes: a role in vitamin D deficiency? J Clin Endocrinol Metab 2011; 96: 142-9.
25. Chun RF, Adams JS, Hewison M,. Back to the future: a new look at 'old' vitamin D. J Endocrinol 2008; 198: 261-9.
26. Arnaud J, Constans J,. Affinity differences for vitamin D metabolites associated with the genetic isoforms of the human serum carrier protein (DBP). Hum Genet 1993; 92: 183-8.
27. Lauridsen AL, Vestergaard P, Hermann AP, et al,. Plasma concentrations of 25-hydroxy-vitamin D and 1,25-dihydroxy-vitamin D are related to the phenotype of Gc (vitamin D-binding protein): a cross-sectional study on 595 early postmenopausal women. Calcif Tissue Int 2005; 77: 15-22.
28. Fang Y, van Meurs JB, Arp P, et al,. Vitamin D binding protein genotype and osteoporosis. Calcif Tissue Int 2009; 85: 85-93.
29. Gozdzik A, Zhu J, Wong BY, Fu L, Cole DE, Parra EJ,. Association of vitamin D binding protein (VDBP) polymorphisms and serum 25(OH)D concentrations in a sample of young Canadian adults of different ancestry. J Steroid Biochem Mol Biol 2011; 127: 405-12.
30. Engelman CD, Fingerlin TE, Langefeld CD, et al,. Genetic and environmental determinants of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels in Hispanic and African Americans. J Clin Endocrinol Metab 2008; 93: 3381-8.
31. Chun RF, Peercy BE, Adams JS, Hewison M,. Vitamin D binding protein and monocyte response to 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D: analysis by mathematical modeling. PLoS ONE 2012; 7: e30773.
32. Jeng L, Yamshchikov AV, Judd SE, et al,. Alterations in vitamin D status and anti-microbial peptide levels in patients in the intensive care unit with sepsis. J Transl Med 2009; 7: 28.
33. Bouillon R, ed. The Vitamin D Binding Protein (DBP). 3rd ed. London: Elsevier, 2011.
34. Zhang J, Kew RR,. Identification of a region in the vitamin D-binding protein that mediates its C5a chemotactic cofactor function. J Biol Chem 2004; 279: 53282-7.
35. Yamamoto N, Naraparaju VR,. Role of vitamin D3-binding protein in activation of mouse macrophages. J Immunol 1996; 157: 1744-9.
36. Anderson LN, Cotterchio M, Cole DE, Knight JA,. Vitamin D-related genetic variants, interactions with vitamin D exposure, and breast cancer risk among Caucasian women in Ontario. Cancer Epidemiol Biomarkers Prev 2011; 20: 1708-17.
37. Abbas S, Linseisen J, Slanger T, et al,. The Gc2 allele of the vitamin D binding protein is associated with a decreased postmenopausal breast cancer risk, independent of the vitamin D status. Cancer Epidemiol Biomarkers Prev 2008; 17: 1339-43.
38. Orton SM, Ramagopalan SV, Para AE, et al,. Vitamin D metabolic pathway genes and risk of multiple sclerosis in Canadians. J Neurol Sci 2011; 305: 116-20.
39. Brumbaugh PF, Haussler MR,. Nuclear and cytoplasmic binding components for vitamin D metabolites. Life Sci 1975; 16: 353-62.
40. Haussler MR, Norman AW,. Chromosomal receptor for a vitamin D metabolite. Proc Natl Acad Sci U S A 1969; 62: 155-62.
41. Baker AR, McDonnell DP, Hughes M, et al,. Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc Natl Acad Sci U S A 1988; 85: 3294-8.
42. Ramagopalan SV, Heger A, Berlanga AJ, et al,. A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res 2010; 20: 1352-60.
43. Norman AW,. Minireview: vitamin D receptor: new assignments for an already busy receptor. Endocrinology 2006; 147: 5542-8.
44. Boland RL,. VDR activation of intracellular signaling pathways in skeletal muscle. Mol Cell Endocrinol 2011; 347: 11-6.
45. Sone T, Marx SJ, Liberman UA, Pike JW,. A unique point mutation in the human vitamin D receptor chromosomal gene confers hereditary resistance to 1,25-dihydroxyvitamin D3. Mol Endocrinol 1990; 4: 623-31.
46. Valdivielso JM, Fernandez E,. Vitamin D receptor polymorphisms and diseases. Clin Chim Acta 2006; 371: 1-12.
47. Cox MB, Ban M, Bowden NA, Baker A, Scott RJ, Lechner-Scott J,. Potential association of vitamin D receptor polymorphism Taq1 with multiple sclerosis. Mult Scler 2012; 18: 16-22.
48. Fukumoto S,. Physiological regulation and disorders of phosphate metabolism-pivotal role of fibroblast growth factor 23. Intern Med 2008; 47: 337-43.
49. Fleet JCS, Schoch RD, ed. Molecular Mechanisms for Regulation of Intestinal Calcium and Phosphate Absorption by Vitamin D. 3rd edn. Oxford, UK: Elsevier, 2011.
50. Marks J, Debnam ES, Unwin RJ,. Phosphate homeostasis and the renal-gastrointestinal axis. Am J Physiol Renal Physiol 2010; 299: F285-96.
51. Anderson PH, Atkins GJ, Turner AG, Kogawa M, Findlay DM, Morris HA,. Vitamin D metabolism within bone cells: effects on bone structure and strength. Mol Cell Endocrinol 2011; 347: 42-7.
52. Perez-Lopez FR,. Vitamin D and its implications for musculoskeletal health in women: an update. Maturitas 2007; 58: 117-37.
53. Christakos S, Deluca HF,. Minireview: vitamin D: is there a role in extraskeletal health? Endocrinology 2011; 152: 2930-6.
54. WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994; 843: 1-129.
55. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE,. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337: 670-6.
56. Chapuy MC, Arlot ME, Duboeuf F, et al,. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992; 327: 1637-42.
57. Chapuy MC, Arlot ME, Delmas PD, Meunier PJ,. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 1994; 308: 1081-2.
58. Chapuy MC, Pamphile R, Paris E, et al,. Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos Int 2002; 13: 257-64.
59. Pfeifer M, Begerow B, Minne HW, Abrams C, Nachtigall D, Hansen C,. Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. J Bone Miner Res 2000; 15: 1113-8.
60. Trivedi DP, Doll R, Khaw KT,. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 2003; 326: 469.
61. Bischoff-Ferrari HA, Shao A, Dawson-Hughes B, Hathcock J, Giovannucci E, Willett WC,. Benefit-risk assessment of vitamin D supplementation. Osteoporos Int 2010; 21: 1121-32.
62. Meyer HE, Smedshaug GB, Kvaavik E, Falch JA, Tverdal A, Pedersen JI,. Can vitamin D supplementation reduce the risk of fracture in the elderly? A randomized controlled trial. J Bone Miner Res 2002; 17: 709-15.
63. Lips P, Graafmans WC, Ooms ME, Bezemer PD, Bouter LM,. Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial. Ann Intern Med 1996; 124: 400-6.
64. Smith H, Anderson F, Raphael H, Maslin P, Crozier S, Cooper C,. Effect of annual intramuscular vitamin D on fracture risk in elderly men and women-a population-based, randomized, double-blind, placebo-controlled trial. Rheumatology (Oxford) 2007; 46: 1852-7.
65. Jackson RD, LaCroix AZ, Gass M, et al,. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006; 354: 669-83.
66. Chapuy MC, Preziosi P, Maamer M, et al,. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int 1997; 7: 439-43.
67. Kuchuk NO, van Schoor NM, Pluijm SM, Chines A, Lips P,. Vitamin D status, parathyroid function, bone turnover, and BMD in postmenopausal women with osteoporosis: global perspective. J Bone Miner Res 2009; 24: 693-701.
68. Priemel M, von Domarus C, Klatte TO, et al,. Bone mineralization defects and vitamin D deficiency: histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. J Bone Miner Res 2010; 25: 305-12.
69. Murad MH, Elamin KB, Abu Elnour NO, et al,. The Effect of Vitamin D on Falls: a Systematic Review and Meta-Analysis. J Clin Endocrinol Metab 2011; 96: 2997-3006.
70. Visser M, Deeg DJ, Lips P,. Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the Longitudinal Aging Study Amsterdam. J Clin Endocrinol Metab 2003; 88: 5766-72.
71. Ceglia L,. Vitamin D and skeletal muscle tissue and function. Mol Aspects Med 2008; 29: 407-14.
72. Stockton KA, Mengersen K, Paratz JD, Kandiah D, Bennell KL,. Effect of vitamin D supplementation on muscle strength: a systematic review and meta-analysis. Osteoporos Int 2011; 22: 859-71.
73. Pike JW, Gooze LL, Haussler MR,. Biochemical evidence for 1,25-dihydroxyvitamin D receptor macromolecules in parathyroid, pancreatic, pituitary, and placental tissues. Life Sci 1980; 6: 407-14.
74. Berger U, Wilson P, McClelland RA, et al,. Immunocytochemical detection of 1,25-dihydroxyvitamin D receptors in normal human tissues. J Clin Endocrinol Metab 1988; 67: 607-13.
75. Miyaura C, Abe E, Kuribayashi T, et al,. 1 alpha,25-Dihydroxyvitamin D3 induces differentiation of human myeloid leukemia cells. Biochem Biophys Res Commun 1981; 102: 937-43.
76. Provvedini DM, Rulot CM, Sobol RE, Tsoukas CD, Manolagas SC,. 1 alpha,25-Dihydroxyvitamin D3 receptors in human thymic and tonsillar lymphocytes. J Bone Miner Res 1987; 2: 239-47.
77. Khan AA, Dragt BS, Porte RJ, Groothuis GM,. Regulation of VDR expression in rat and human intestine and liver-consequences for CYP3A expression. Toxicol In Vitro 2010; 24: 822-9.
78. Zehnder D, Bland R, Williams MC, et al,. Extrarenal expression of 25-hydroxyvitamin D(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab 2001; 86: 888-94.
79. Adams JS, Sharma OP, Gacad MA, Singer FR,. Metabolism of 25-hydroxyvitamin D3 by cultured pulmonary alveolar macrophages in sarcoidosis. J Clin Invest 1983; 72: 1856-60.
80. McLeod JF, Cooke NE,. The vitamin D-binding protein, alpha-fetoprotein, albumin multigene family: detection of transcripts in multiple tissues. J Biol Chem 1989; 264: 21760-9.
81. Cunningham J, Zehnder D,. New vitamin D analogs and changing therapeutic paradigms. Kidney Int 2011; 79: 702-7.
82. Ross AC, Manson JE, Abrams SA, et al,. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011; 96: 53-8.
83. Pilz S, Tomaschitz A, Marz W, et al,. Vitamin D, cardiovascular disease and mortality. Clin Endocrinol (Oxf) 2011; 75: 575-84.
84. Zhang Z, Zhang Y, Ning G, Deb DK, Kong J, Li YC,. Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci U S A 2008; 105: 15896-901.
85. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP,. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110: 229-38.
86. Deb DK, Sun T, Wong KE, et al,. Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes. Kidney Int 2010; 77: 1000-9.
87. Davis CD, Milner JA,. Vitamin D and colon cancer. Expert Rev Gastroenterol Hepatol 2011; 5: 67-81.
88. Murillo G, Nagpal V, Tiwari N, Benya RV, Mehta RG,. Actions of vitamin D are mediated by the TLR4 pathway in inflammation-induced colon cancer. J Steroid Biochem Mol Biol 2010; 121: 403-7.
89. Lagishetty V, Chun RF, Liu NQ, Lisse TS, Adams JS, Hewison M,. 1alpha-hydroxylase and innate immune responses to 25-hydroxyvitamin D in colonic cell lines. J Steroid Biochem Mol Biol 2010; 121: 228-33.
90. Welsh J,. Vitamin D metabolism in mammary gland and breast cancer. Mol Cell Endocrinol 2011; 347: 55-60.
91. Lundqvist J, Norlin M, Wikvall K,. 1alpha,25-Dihydroxyvitamin D3 exerts tissue-specific effects on estrogen and androgen metabolism. Biochim Biophys Acta 2011; 1811: 263-70.
92. Hidalgo AA, Montecinos VP, Paredes R, et al,. Biochemical characterization of nuclear receptors for vitamin D(3) and glucocorticoids in prostate stroma cell microenvironment. Biochem Biophys Res Commun 2011; 412: 13-9.
93. Okamoto R, Delansorne R, Wakimoto N, et al,. Inecalcitol, an analog of 1alpha,25(OH)(2) D(3), induces growth arrest of androgen-dependent prostate cancer cells. Int J Cancer 2012; 130: 2464-73.
94. Deeb KK, Luo W, Karpf AR, et al,. Differential vitamin D 24-hydroxylase/CYP24A1 gene promoter methylation in endothelium from benign and malignant human prostate. Epigenetics 2011; 6: 994-1000.
95. Szendroi A, Speer G, Tabak A, et al,. The role of vitamin D, estrogen, calcium sensing receptor genotypes and serum calcium in the pathogenesis of prostate cancer. Can J Urol 2011; 18: 5710-6.
96. Munetsuna E, Nakabayashi S, Kawanami R, et al,. Mechanism of the Anti-proliferative Action of 25-Hydroxy-19-nor-vitamin D3 in Human Prostate Cells. J Mol Endocrinol 2011; 47: 209-18.
97. Swami S, Krishnan AV, Feldman D,. Vitamin D metabolism and action in the prostate: implications for health and disease. Mol Cell Endocrinol 2011; 347: 61-9.
98. Keet CA, McCormack MC, Peng RD, Matsui EC,. Age- and atopy-dependent effects of vitamin D on wheeze and asthma. J Allergy Clin Immunol 2011; 128: 414-6 e5.
99. Hansdottir S, Monick MM,. Vitamin D effects on lung immunity and respiratory diseases. Vitam Horm 2011; 86: 217-37.
100. Zosky GR, Berry LJ, Elliot JG, James AL, Gorman S, Hart PH,. Vitamin D deficiency causes deficits in lung function and alters lung structure. Am J Respir Crit Care Med 2011; 183: 1336-43.
101. Akbar NA, Zacharek MA,. Vitamin D: immunomodulation of asthma, allergic rhinitis, and chronic rhinosinusitis. Curr Opin Otolaryngol Head Neck Surg 2011; 19: 224-8.
102. Martineau AR, Timms PM, Bothamley GH, et al,. High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet 2011; 377: 242-50.
103. de Zeeuw D, Agarwal R, Amdahl M, et al,. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010; 376: 1543-51.
104. Manson JE, Mayne ST, Clinton SK,. Vitamin D and prevention of cancer-ready for prime time? N Engl J Med 2011; 364: 1385-7.
105. Agarwal R,. Are vitamin D receptor agonists like angiotensin-converting enzyme inhibitors without side effects? Kidney Int 2010; 77: 943-5.
106. Herr C, Greulich T, Koczulla RA, et al,. The role of vitamin D in pulmonary disease: COPD, asthma, infection, and cancer. Respir Res 2011; 12: 31.
107. Shapses SA, Manson JE,. Vitamin D and prevention of cardiovascular disease and diabetes: why the evidence falls short. JAMA 2011; 305: 2565-6.
108. Pilz S, Iodice S, Zittermann A, Grant WB, Gandini S,. Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. Am J Kidney Dis 2011; 58: 374-82.
109. Gravellone L, Rizzo MA, Martina V, Mezzina N, Regalia A, Gallieni M,. Vitamin D receptor activators and clinical outcomes in chronic kidney disease. Int J Nephrol 2011; 2011: 419524.
110. Barnett CM, Beer TM,. Prostate cancer and vitamin D: what does the evidence really suggest? Urol Clin North Am 2011; 38: 333-42.
111. Maxwell CS, Wood RJ,. Update on vitamin D and type 2 diabetes. Nutr Rev 2011; 69: 291-5.
112. Ulitsky A, Ananthakrishnan AN, Naik A, et al,. Vitamin D deficiency in patients with inflammatory bowel disease: association with disease activity and quality of life. JPEN J Parenter Enteral Nutr 2011; 35: 308-16.
113. Silvennoinen J,. Relationships between vitamin D, parathyroid hormone and bone mineral density in inflammatory bowel disease. J Intern Med 1996; 239: 131-7.
114. Tajika M, Matsuura A, Nakamura T, et al,. Risk factors for vitamin D deficiency in patients with Crohn's disease. J Gastroenterol 2004; 39: 527-33.
115. McCarthy D, Duggan P, O'Brien M, et al,. Seasonality of vitamin D status and bone turnover in patients with Crohn's disease. Aliment Pharmacol Ther 2005; 21: 1073-83.
116. Siffledeen JS, Siminoski K, Steinhart H, Greenberg G, Fedorak RN,. The frequency of vitamin D deficiency in adults with Crohn's disease. Can J Gastroenterol 2003; 17: 473-8.
117. Levin AD, Wadhera V, Leach ST, et al,. Vitamin D deficiency in children with inflammatory bowel disease. Dig Dis Sci 2011; 56: 830-6.
118. Ghishan FK, Kiela PR,. Advances in the understanding of mineral and bone metabolism in inflammatory bowel diseases. Am J Physiol Gastrointest Liver Physiol 2011; 300: G191-201.
119. van Hogezand RA, Hamdy NA,. Skeletal morbidity in inflammatory bowel disease. Scand J Gastroenterol Suppl 2006; 59-64.
120. Etzel JP, Larson MF, Anawalt BD, Collins J, Dominitz JA,. Assessment and management of low bone density in inflammatory bowel disease and performance of professional society guidelines. Inflamm Bowel Dis 2011; 17: 2122-9.
121. Veerappan SG, O'Morain CA, Daly JS, Ryan BM,. Review article: the effects of antitumour necrosis factor-alpha on bone metabolism in inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33: 1261-72.
122. Lee Y, Kim M, Choi K, et al,. Relationship between inflammation biomarkers, antioxidant vitamins, and bone mineral density in patients with metabolic syndrome. Nutr Res Pract 2011; 5: 150-6.
123. van Staa TP, Cooper C, Brusse LS, Leufkens H, Javaid MK, Arden NK,. Inflammatory bowel disease and the risk of fracture. Gastroenterology 2003; 125: 1591-7.
124. Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN,. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med 2000; 133: 795-9.
125. Lewis NR,. Guidelines for osteoporosis in inflammatory bowel disease and coeliac disease. 2007. Available at:. Accessed January 15, 2012.
126. Clinical practice committee. American Gastroenterological Association medical position statement: guidelines on osteoporosis in gastrointestinal diseases. Gastroenterology 2003; 124: 791-4.
127. Kornbluth A, Hayes M, Feldman S, et al,. Do guidelines matter? Implementation of the ACG and AGA osteoporosis screening guidelines in inflammatory bowel disease (IBD) patients who meet the guidelines' criteria. Am J Gastroenterol 2006; 101: 1546-50.
128. Miheller P, Muzes G, Hritz I, et al,. Comparison of the effects of 1,25 dihydroxyvitamin D and 25 hydroxyvitamin D on bone pathology and disease activity in Crohn's disease patients. Inflamm Bowel Dis 2009; 15: 1656-62.
129. Vogelsang H, Ferenci P, Resch H, Kiss A, Gangl A,. Prevention of bone mineral loss in patients with Crohn's disease by long-term oral vitamin D supplementation. Eur J Gastroenterol Hepatol 1995; 7: 609-14.
130. Bechtold S, Alberer M, Arenz T, et al,. Reduced muscle mass and bone size in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2010; 16: 216-25.
131. Schneider SM, Al-Jaouni R, Filippi J, et al,. Sarcopenia is prevalent in patients with Crohn's disease in clinical remission. Inflamm Bowel Dis 2008; 14: 1562-8.
132. Cuoco L, Vescovo G, Castaman R, et al,. Skeletal muscle wastage in Crohn's disease: a pathway shared with heart failure? Int J Cardiol 2008; 127: 219-27.
133. Shivananda S, Lennard-Jones J, Logan R, et al,. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 1996; 39: 690-7.
134. Khalili H, Huang ES, Ananthakrishnan AN, et al,. Geographical variation and incidence of inflammatory bowel disease among US women. Gut 2012 [Epub ahead of print].
135. Baumgart DC, Bernstein CN, Abbas Z, et al,. IBD Around the world: comparing the epidemiology, diagnosis, and treatment: proceedings of the World Digestive Health Day 2010-Inflammatory bowel disease task force meeting. Inflamm Bowel Dis 2011; 17: 639-44.
136. Gearry RB, Richardson A, Frampton CM, et al,. High incidence of Crohn's disease in Canterbury, New Zealand: results of an epidemiologic study. Inflamm Bowel Dis 2006; 12: 936-43.
137. Carr I, Mayberry JF,. The effects of migration on ulcerative colitis: a three-year prospective study among Europeans and first- and second- generation South Asians in Leicester (1991-1994). Am J Gastroenterol 1999; 94: 2918-22.
138. Moum B, Aadland E, Ekbom A, Vatn MH,. Seasonal variations in the onset of ulcerative colitis. Gut 1996; 38: 376-8.
139. Zeng L, Anderson FH,. Seasonal change in the exacerbations of Crohn's disease. Scand J Gastroenterol 1996; 31: 79-82.
140. Nerich V, Jantchou P, Boutron-Ruault MC, et al,. Low exposure to sunlight is a risk factor for Crohn's disease. Aliment Pharmacol Ther 2011; 33: 940-5.
141. Ananthakrishnan AN, Khalili H, Higuchi LM, et al,. Higher predicted vitamin D status is associated with reduced risk of Crohn's disease. Gastroenterology 2012; 142: 482-9.
142. Cario E,. Heads up! How the intestinal epithelium safeguards mucosal barrier immunity through the inflammasome and beyond. Curr Opin Gastroenterol 2010; 26: 583-90.
143. Henderson P, van Limbergen JE, Schwarze J, Wilson DC,. Function of the intestinal epithelium and its dysregulation in inflammatory bowel disease. Inflamm Bowel Dis 2011; 17: 382-95.
144. Scharl M, Paul G, Weber A, et al,. Protection of epithelial barrier function by the Crohn's disease associated gene protein tyrosine phosphatase n2. Gastroenterology 2009; 137: 2030-40 e5.
145. Kaser A, Zeissig S, Blumberg RS,. Inflammatory bowel disease. Annu Rev Immunol 2010; 28: 573-621.
146. Waterman M, Xu W, Stempak JM, et al,. Distinct and overlapping genetic loci in Crohn's disease and ulcerative colitis: correlations with pathogenesis. Inflamm Bowel Dis 2011; 17: 1936-42.
147. Kong J, Zhang Z, Musch MW, et al,. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. Am J Physiol Gastrointest Liver Physiol 2008; 294: G208-16.
148. Abraham C, Medzhitov R,. Interactions between the host innate immune system and microbes in inflammatory bowel disease. Gastroenterology 2011; 140: 1729-37.
149. Inohara N, Ogura Y, Fontalba A, et al,. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J Biol Chem 2003; 278: 5509-12.
150. Sabbah A, Chang TH, Harnack R, et al,. Activation of innate immune antiviral responses by Nod2. Nat Immunol 2009; 10: 1073-80.
151. Hugot JP, Chamaillard M, Zouali H, et al,. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411: 599-603.
152. Brennan A, Katz DR, Nunn JD, et al,. Dendritic cells from human tissues express receptors for the immunoregulatory vitamin D3 metabolite, dihydroxycholecalciferol. Immunology 1987; 61: 457-61.
153. Yuk JM, Shin DM, Lee HM, et al,. Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin. Cell Host Microbe 2009; 6: 231-43.
154. Wang TT, Dabbas B, Laperriere D, et al,. Direct and indirect induction by 1,25-dihydroxyvitamin D3 of the NOD2/CARD15-defensin beta2 innate immune pathway defective in Crohn disease. J Biol Chem 2010; 285: 2227-31.
155. Kaser A, Blumberg RS,. Autophagy, microbial sensing, endoplasmic reticulum stress, and epithelial function in inflammatory bowel disease. Gastroenterology 2011; 140: 1738-47.
156. Grant SF, Baldassano RN, Hakonarson H,. Classification of genetic profiles of Crohn's disease: a focus on the ATG16L1 gene. Expert Rev Mol Diagn 2008; 8: 199-207.
157. Verway M, Behr MA, White JH,. Vitamin D, NOD2, autophagy and Crohn's disease. Expert Rev Clin Immunol 2010; 6: 505-8.
158. Schauber J, Rieger D, Weiler F, et al,. Heterogeneous expression of human cathelicidin hCAP18/LL-37 in inflammatory bowel diseases. Eur J Gastroenterol Hepatol 2006; 18: 615-21.
159. Koon HW, Shih DQ, Chen J, et al,. Cathelicidin signaling via the toll-like receptor protects against colitis in mice. Gastroenterology 2011; 141: 1852-63.
160. Tai EK, Wu WK, Wong HP, Lam EK, Yu L, Cho CH,. A new role for cathelicidin in ulcerative colitis in mice. Exp Biol Med (Maywood) 2007; 232: 799-808.
161. Stio M, Martinesi M, Bruni S, et al,. Interaction among vitamin D(3) analogue KH 1060, TNF-alpha, and vitamin D receptor protein in peripheral blood mononuclear cells of inflammatory bowel disease patients. Int Immunopharmacol 2006; 6: 1083-92.
162. Penna G, Adorini L,. 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 2000; 164: 2405-11.
163. Griffin MD, Lutz WH, Phan VA, Bachman LA, McKean DJ, Kumar R,. Potent inhibition of dendritic cell differentiation and maturation by vitamin D analogs. Biochem Biophys Res Commun 2000; 270: 701-8.
164. Szeles L, Keresztes G, Torocsik D, et al,. 1,25-dihydroxyvitamin D3 is an autonomous regulator of the transcriptional changes leading to a tolerogenic dendritic cell phenotype. J Immunol 2009; 182: 2074-83.
165. Strober W, Fuss IJ,. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011; 140: 1756-67.
166. Rovedatti L, Kudo T, Biancheri P, et al,. Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. Gut 2009; 58: 1629-36.
167. Jeffery LE, Burke F, Mura M, et al,. 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J Immunol 2009; 183: 5458-67.
168. De Nitto D, Sarra M, Pallone F, Monteleone G,. Interleukin-21 triggers effector cell responses in the gut. World J Gastroenterol 2010; 16: 3638-41.
169. Yu S, Bruce D, Froicu M, Weaver V, Cantorna MT,. Failure of T cell homing, reduced CD4/CD8alphaalpha intraepithelial lymphocytes, and inflammation in the gut of vitamin D receptor KO mice. Proc Natl Acad Sci U S A 2008; 105: 20834-9.
170. Cantorna MT, Munsick C, Bemiss C, Mahon BD,. 1,25- Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr 2000; 130: 2648-52.
171. Daniel C, Sartory NA, Zahn N, Radeke HH, Stein JM,. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. J Pharmacol Exp Ther 2008; 324: 23-33.
172. Laverny G, Penna G, Vetrano S, et al,. Efficacy of a potent and safe vitamin D receptor agonist for the treatment of inflammatory bowel disease. Immunol Lett 2010; 131: 49-58.
173. + T cells from patients with Crohn's disease. Int Immunopharmacol 2007; 7: 1755-64.
174. Niino M,. Vitamin D and its immunoregulatory role in multiple sclerosis. Drugs Today (Barc) 2010; 46: 279-90.
175. Pelajo CF, Lopez-Benitez JM, Miller LC,. Vitamin D and autoimmune rheumatologic disorders. Autoimmun Rev 2010; 9: 507-10.
176. Fowlkes JL, Bunn RC, Cockrell GE, et al,. Dysregulation of the intrarenal vitamin D endocytic pathway in a nephropathy-prone mouse model of type 1 diabetes. Exp Diabetes Res 2011; 2011: 269378.
177. Simmons JD, Mullighan C, Welsh KI, Jewell DP,. Vitamin D receptor gene polymorphism: association with Crohn's disease susceptibility. Gut 2000; 47: 211-4.
178. Bentley RW, Keown D, Merriman TR, et al,. Vitamin D receptor gene polymorphism associated with inflammatory bowel disease in New Zealand males. Aliment Pharmacol Ther 2011; 33: 855-6.
179. Noble CL, McCullough J, Ho W, et al,. Low body mass not vitamin D receptor polymorphisms predict osteoporosis in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2008; 27: 588-96.
180. Naderi N, Farnood A, Habibi M, et al,. Association of vitamin D receptor gene polymorphisms in Iranian patients with inflammatory bowel disease. J Gastroenterol Hepatol 2008; 23: 1816-22.
181. Hughes DJ, McManus R, Neary P, O'Morain C, O'Sullivan M,. Common variation in the vitamin D receptor gene and risk of inflammatory bowel disease in an Irish case-control study. Eur J Gastroenterol Hepatol 2011; 23: 807-12.
182. Eloranta JJ, Wenger C, Mwinyi J, et al,. Association of a common vitamin D-binding protein polymorphism with inflammatory bowel disease. Pharmacogenet Genomics 2011; 21: 559-64.
183. Jorgensen SP, Agnholt J, Glerup H, et al,. Clinical trial: vitamin D3 treatment in Crohn's disease-a randomized double-blind placebo-controlled study. Aliment Pharmacol Ther 2010; 32: 377-83.
184. Bendix-Struve M, Bartels LE, Agnholt J, Dige A, Jorgensen SP, Dahlerup JF,. Vitamin D3 treatment of Crohn's disease patients increases stimulated T cell IL-6 production and proliferation. Aliment Pharmacol Ther 2010; 32: 1364-72.
185. Boothe DL, Lakehomer H, Jacob V, Scherl E, Bosworth B,. High Dose Vitamin D Improves Clinical Activity in Crohn's Disease. Washington, DC: American College of Gastroenterology, 2011.
186. Abreu MT, Kantorovich V, Vasiliauskas EA, et al,. Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn's disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density. Gut 2004; 53: 1129-36.
187. Wada K, Tanaka H, Maeda K, et al,. Vitamin D receptor expression is associated with colon cancer in ulcerative colitis. Oncol Rep 2009; 22: 1021-5.
188. Healy KD, Zella JB, Prahl JM, DeLuca HF,. Regulation of the murine renal vitamin D receptor by 1,25-dihydroxyvitamin D3 and calcium. Proc Nat Acad Sci USA 2003; 100: 9733-7.
189. Pike JW, ed. The Vitamin D Receptor. 3rd ed. London: Elsevier, 2011.
190. Ullman TA, Itzkowitz SH,. Intestinal inflammation and cancer. Gastroenterology 2011; 140: 1807-16.
191. Cross HS, Peterlik M, Reddy GS, Schuster I,. Vitamin D metabolism in human colon adenocarcinoma-derived Caco-2 cells: expression of 25-hydroxyvitamin D3-1alpha-hydroxylase activity and regulation of side-chain metabolism. J Steroid Biochem Mol Biol 1997; 62: 21-8.
192. Yang K, Lipkin M, Newmark H, et al,. Molecular targets of calcium and vitamin D in mouse genetic models of intestinal cancer. Nutr Rev 2007; 65: S134-7.
193. Cross HS, Nittke T, Kallay E,. Colonic vitamin D metabolism: implications for the pathogenesis of inflammatory bowel disease and colorectal cancer. Mol Cell Endocrinol 2011; 347: 70-9.
194. Yang K, Kurihara N, Fan K, et al,. Dietary induction of colonic tumors in a mouse model of sporadic colon cancer. Cancer Res 2008; 68: 7803-10.
195. Newmark HL, Yang K, Kurihara N, Fan K, Augenlicht LH, Lipkin M,. Western-style diet-induced colonic tumors and their modulation by calcium and vitamin D in C57Bl/6 mice: a preclinical model for human sporadic colon cancer. Carcinogenesis 2009; 30: 88-92.
196. Bouillon R, Carmeliet G, Verlinden L, et al,. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev 2008; 29: 726-76.
197. Ross AC, ed. Institute of Medicine of the National Academies 2011 Dietary Reference Intakes for Calcium and Vitamin D. Washington DC: The National Academies Press, 2011.
198. Freedman DM, Looker AC, Abnet CC, Linet MS, Graubard BI,. Serum 25-hydroxyvitamin D and cancer mortality in the NHANES III study (1988-2006). Cancer Res 2010; 70: 8587-97.
199. Jenab M, Bueno-de-Mesquita HB, Ferrari P, et al,. Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations: a nested case-control study. BMJ 2010; 340: b5500.
200. Weinstein SJ, Yu K, Horst RL, Ashby J, Virtamo J, Albanes D,. Serum 25-hydroxyvitamin D and risks of colon and rectal cancer in Finnish men. Am J Epidemiol 2011; 173: 499-508.
201. Wactawski-Wende J, Kotchen JM, Anderson GL, et al,. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006; 354: 684-96.
202. Berry D, Hypponen E,. Determinants of vitamin D status: focus on genetic variations. Curr Opin Nephrol Hypertens 2011; 20: 331-6.
203. Norman AW, Bouillon R,. Vitamin D nutritional policy needs a vision for the future. Exp Biol Med (Maywood) 2010; 235: 1034-45.
204. Melamed ML, Michos ED, Post W, Astor B,. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008; 168: 1629-37.
205. Visser M, Deeg DJ, Puts MT, Seidell JC, Lips P,. Low serum concentrations of 25-hydroxyvitamin D in older persons and the risk of nursing home admission. Am J Clin Nutr 2006; 84: 616-22.
206. Raman M, Milestone AN, Walters JR, Hart AL, Ghosh S,. Vitamin D and gastrointestinal diseases: inflammatory bowel disease and colorectal cancer. Therap Adv Gastroenterol 2011; 4: 49-62.
207. Larsen ER, Mosekilde L, Foldspang A,. Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study. J Bone Miner Res 2004; 19: 370-8.
208. Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ,. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 2003; 77: 204-10.
209. Farraye FA, Nimitphong H, Stucchi A, et al,. Use of a novel vitamin D bioavailability test demonstrates that vitamin D absorption is decreased in patients with quiescent Crohn's disease. Inflamm Bowel Dis 2011; 17: 2116-21.
210. Pekkarinen T, Valimaki VV, Aarum S, et al,. The same annual dose of 292000 IU of vitamin D (cholecalciferol) on either daily or four monthly basis for elderly women: 1-year comparative study of the effects on serum 25(OH)D concentrations and renal function. Clin Endocrinol (Oxf) 2010; 72: 455-61.
211. Hackman KL, Gagnon C, Briscoe RK, Lam S, Anpalahan M, Ebeling PR,. Efficacy and safety of oral continuous low-dose versus short-term high-dose vitamin D: a prospective randomised trial conducted in a clinical setting. Med J Aust 2010; 192: 686-9.
212. von Restorff C, Bischoff-Ferrari HA, Theiler R,. High-dose oral vitamin D3 supplementation in rheumatology patients with severe vitamin D3 deficiency. Bone 2009; 45: 747-9.
213. Diamond TH, Ho KW, Rohl PG, Meerkin M,. Annual intramuscular injection of a megadose of cholecalciferol for treatment of vitamin D deficiency: efficacy and safety data. Med J Aust 2005; 183: 10-2.
214. Trang HM, Cole DE, Rubin LA, Pierratos A, Siu S, Vieth R,. Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. Am J Clin Nutr 1998; 68: 854-8.
215. Holick MF, Biancuzzo RM, Chen TC, et al,. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab 2008; 93: 677-81.
216. Binkley N, Gemar D, Engelke J, et al,. Evaluation of ergocalciferol or cholecalciferol dosing, 1,600 IU daily or 50,000 IU monthly in older adults. J Clin Endocrinol Metab 2011; 96: 981-8.
217. O'Neill JL, Feldman SR,. Vitamine D analogue-based therapies for psoriasis. Drugs Today (Barc) 2010; 46: 351-60.
218. Adorini L,. Intervention in autoimmunity: the potential of vitamin D receptor agonists. Cell Immunol 2005; 233: 115-24.
219. Binkley N, Krueger D, Gemar D, Drezner MK,. Correlation among 25-hydroxy-vitamin D assays. J Clin Endocrinol Metab 2008; 93: 1804-8.
220. Binkley N, Krueger D, Cowgill CS, et al,. Assay variation confounds the diagnosis of hypovitaminosis D: a call for standardization. J Clin Endocrinol Metab 2004; 89: 3152-7.
221. Wang TJ, Zhang F, Richards JB, et al,. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet 2010; 376: 180-8.